Secretory iga and course of covid-19 in patients receiving a bacteria-based immunostimulant agent in addition to background therapy

HIGHLIGHTS

• What: The aims were to evaluate the changes in sIgA levels taken from various loci of the upper respiratory tract in COVID-19 patients from the moment of admission to the hospital, on days 14 and 30 and to assess the impact of a bacteria-based immunostimulant on the secretion of sIgA, the duration of fever, the number of hospital days, and the CRP level. When the model was created, goodness-of-fit tests (normality of distribution and homogeneity of variance in residuals) were conducted using the DHARMa ­package25.
• Who: Mikhail Kostinov from the DepartmentMedical . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.